Robert B Bazemore Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Robert B Bazemore.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Robert B Bazemore. Robert B Bazemore is Chief Operating Officer in SYNAGEVA BIOPHARMA CORP ($GEVA) and Director in ARDELYX, INC. ($ARDX) and President & CEO in Epizyme, Inc. ($EPZM) and Director in Neon Therapeutics, Inc. ($NTGN) and Director in Nuvation Bio Inc. ($PANA).
Latest Insider Trading Transactions of Robert B Bazemore
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, ARDX, EPZM, NTGN, NUVB, GEVA
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 01 2021 | NUVB | Nuvation Bio Inc. | Bazemore Robert B | Director | Buy | P | 9.98 | 5,000 | 49,900 | 5,000 | 0 to 5 K |
| Feb 12 2021 | PANA | Nuvation Bio Inc. | Bazemore Robert B | Director | Option Exercise | A | 1.74 | 187,658 | 326,525 | 187,658 | |
| Feb 12 2021 | PANA | Nuvation Bio Inc. | Bazemore Robert B | Director | Option Exercise | A | 4.60 | 51,703 | 237,834 | 51,703 | |
| Feb 05 2021 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Sell | S | 11.21 | 3,890 | 43,607 | 331,977 | 335.9 K to 332 K (-1.16 %) |
| Feb 02 2021 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Option Exercise | A | 11.02 | 417,443 | 4,600,222 | 417,443 | |
| Feb 02 2021 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Grant | A | 0.00 | 87,500 | 0 | 335,867 | 248.4 K to 335.9 K (+35.23 %) |
| Jan 27 2021 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Sell | S | 11.41 | 6,069 | 69,247 | 248,367 | 254.4 K to 248.4 K (-2.39 %) |
| Jun 30 2020 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Sell | S | 16.15 | 4,773 | 77,084 | 250,098 | 254.9 K to 250.1 K (-1.87 %) |
| Jun 30 2020 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Grant | A | 0.00 | 10,500 | 0 | 254,871 | 244.4 K to 254.9 K (+4.30 %) |
| Jun 22 2020 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Option Exercise | M | 8.98 | 10,000 | 89,800 | 323,333 | |
| Jun 22 2020 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Sell | S | 22.00 | 10,000 | 220,000 | 244,371 | 254.4 K to 244.4 K (-3.93 %) |
| Jun 22 2020 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Sell | S | 22.00 | 10,000 | 220,000 | 254,371 | 264.4 K to 254.4 K (-3.78 %) |
| Jun 22 2020 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Buy | M | 8.98 | 10,000 | 89,800 | 264,371 | 254.4 K to 264.4 K (+3.93 %) |
| Jun 11 2020 | ARDX | ARDELYX, INC. | Bazemore Robert B | Director | Option Exercise | A | 7.31 | 23,500 | 171,785 | 23,500 | |
| May 06 2020 | NTGN | Neon Therapeutics, ... | Bazemore Robert B | Director | Option Exercise | D | 4.64 | 18,500 | 85,840 | 0 | |
| May 06 2020 | NTGN | Neon Therapeutics, ... | Bazemore Robert B | Director | Option Exercise | D | 7.56 | 28,000 | 211,680 | 0 | |
| Mar 26 2020 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Option Exercise | A | 16.14 | 73,409 | 1,184,821 | 73,409 | |
| Mar 26 2020 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Option Exercise | J | 9.12 | 48,727 | 444,390 | 298,737 | |
| Mar 26 2020 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Option Exercise | J | 12.45 | 2,371 | 29,519 | 333,333 | |
| Mar 26 2020 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Option Exercise | J | 8.98 | 79,167 | 710,920 | 333,333 | |
| Mar 26 2020 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Sell | S | 15.28 | 3,285 | 50,195 | 254,371 | 257.7 K to 254.4 K (-1.27 %) |
| Mar 26 2020 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Grant | A | 0.00 | 7,000 | 0 | 257,656 | 250.7 K to 257.7 K (+2.79 %) |
| Mar 26 2020 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Grant | A | 0.00 | 113,393 | 0 | 250,656 | 137.3 K to 250.7 K (+82.61 %) |
| Mar 26 2020 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Sell | J | 0.00 | 56,537 | 0 | 80,726 | 137.3 K to 80.7 K (-41.19 %) |
| Mar 26 2020 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Option Exercise | A | 16.14 | 73,409 | 1,184,821 | 73,409 | |
| Mar 26 2020 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Option Exercise | J | 9.12 | 48,727 | 444,390 | 298,737 | |
| Mar 26 2020 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Option Exercise | J | 12.45 | 2,371 | 29,519 | 333,333 | |
| Mar 26 2020 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Option Exercise | J | 8.98 | 79,167 | 710,920 | 333,333 | |
| Mar 26 2020 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Sell | S | 15.28 | 3,285 | 50,195 | 254,371 | 257.7 K to 254.4 K (-1.27 %) |
| Mar 26 2020 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Grant | A | 0.00 | 7,000 | 0 | 257,656 | 250.7 K to 257.7 K (+2.79 %) |
| Mar 26 2020 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Grant | A | 0.00 | 113,393 | 0 | 250,656 | 137.3 K to 250.7 K (+82.61 %) |
| Mar 26 2020 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Sell | J | 0.00 | 56,537 | 0 | 80,726 | 137.3 K to 80.7 K (-41.19 %) |
| Feb 05 2020 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Option Exercise | A | 21.39 | 252,956 | 5,410,729 | 252,956 | |
| Feb 05 2020 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Grant | A | 0.00 | 52,595 | 0 | 137,263 | 84.7 K to 137.3 K (+62.12 %) |
| Jan 27 2020 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Sell | S | 20.44 | 6,074 | 124,153 | 84,668 | 90.7 K to 84.7 K (-6.69 %) |
| Jan 27 2020 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Sell | S | 24.62 | 3,002 | 73,909 | 90,742 | 93.7 K to 90.7 K (-3.20 %) |
| Jan 27 2020 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Grant | A | 0.00 | 8,750 | 0 | 93,744 | 85 K to 93.7 K (+10.29 %) |
| Jun 27 2019 | NTGN | Neon Therapeutics, ... | Bazemore Robert B | Director | Option Exercise | A | 4.64 | 18,500 | 85,840 | 18,500 | |
| Jun 17 2019 | ARDX | ARDELYX, INC. | Bazemore Robert B | Director | Option Exercise | A | 2.74 | 50,000 | 137,000 | 50,000 | |
| Jun 14 2019 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Sell | S | 12.10 | 2,074 | 25,095 | 84,994 | 87.1 K to 85 K (-2.38 %) |
| Jun 14 2019 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Grant | A | 0.00 | 7,000 | 0 | 87,068 | 80.1 K to 87.1 K (+8.74 %) |
| Jan 28 2019 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Option Exercise | A | 9.12 | 347,464 | 3,168,872 | 347,464 | |
| Jan 28 2019 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Grant | A | 0.00 | 75,383 | 0 | 80,068 | 4.7 K to 80.1 K (+1,609.03 %) |
| Jan 28 2019 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Option Exercise | A | 9.12 | 347,464 | 3,168,872 | 347,464 | |
| Jan 28 2019 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Grant | A | 0.00 | 75,383 | 0 | 80,068 | 4.7 K to 80.1 K (+1,609.03 %) |
| Nov 07 2018 | NTGN | Neon Therapeutics, ... | Bazemore Robert B | Director | Option Exercise | A | 7.56 | 28,000 | 211,680 | 28,000 | |
| Nov 07 2018 | NTGN | Neon Therapeutics, ... | Bazemore Robert B | Director | Option Exercise | A | 7.56 | 28,000 | 211,680 | 28,000 | |
| Jun 15 2018 | ARDX | ARDELYX, INC. | Bazemore Robert B | Director | Option Exercise | A | 4.03 | 15,000 | 60,450 | 15,000 | |
| Feb 13 2018 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Option Exercise | A | 16.00 | 265,860 | 4,253,760 | 265,860 | |
| Jun 09 2017 | ARDX | ARDELYX, INC. | Bazemore Robert B | Director | Option Exercise | A | 4.30 | 15,000 | 64,500 | 15,000 | |
| Feb 09 2017 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Option Exercise | A | 12.45 | 335,704 | 4,179,515 | 335,704 | |
| Sep 01 2016 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Grant | A | 6.21 | 1,362 | 8,463 | 1,362 | 0 to 1.4 K |
| Jun 06 2016 | ARDX | ARDELYX, INC. | Bazemore Robert B | Director | Option Exercise | A | 9.27 | 25,000 | 231,750 | 25,000 | |
| Feb 10 2016 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Option Exercise | A | 8.98 | 412,500 | 3,704,250 | 412,500 | |
| Jun 23 2015 | GEVA | SYNAGEVA BIOPHARMA ... | Bazemore Robert B | Chief Operating Off ... | Option Exercise | D | 63.11 | 50,000 | 3,155,500 | 0 | |
| Jun 23 2015 | GEVA | SYNAGEVA BIOPHARMA ... | Bazemore Robert B | Chief Operating Off ... | Sell | D | 0.00 | 35,000 | 0 | 0 | 35 K to 0 (-100.00 %) |
| Jun 09 2015 | GEVA | SYNAGEVA BIOPHARMA ... | Bazemore Robert B | Chief Operating Off ... | Grant | A | 0.00 | 5,000 | 0 | 35,000 | 30 K to 35 K (+16.67 %) |
| Sep 25 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Bazemore Robert B | Chief Operating Off ... | Option Exercise | A | 63.11 | 50,000 | 3,155,500 | 50,000 | |
| Sep 25 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Bazemore Robert B | Chief Operating Off ... | Grant | A | 0.00 | 30,000 | 0 | 30,000 | 0 to 30 K |
Page: 1